• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Repare Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/3/25 7:13:51 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPTX alert in real time by email
    8-K
    false000180815800-000000000018081582025-03-032025-03-03

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 03, 2025

     

     

    Repare Therapeutics Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Quebec

    001-39335

    Not applicable

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    7171 Frederick-Banting, Building 2

    Suite 270

     

    St-Laurent, Quebec, Canada

     

    H4S 1Z9

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 857 412-7018

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common shares, no par value

     

    RPTX

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 3, 2025, Repare Therapeutics Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the three and twelve months ended December 31, 2024. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

    The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    Exhibit

    No.

    Description

    99.1

    Press Release dated March 3, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    REPARE THERAPEUTICS INC.

     

     

     

     

    Date:

     March 3, 2025

    By:

    /s/ Lloyd M. Segal

     

     

     

    Lloyd M. Segal
    President and Chief Executive Officer

     


    Get the next $RPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPTX

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    More analyst ratings

    $RPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/17/23 4:54:43 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/3/23 5:37:44 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • SVP, Finance and CAO Alves Sandra Isabelle Barros was granted 4,100 shares, increasing direct ownership by 16% to 29,622 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:07:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)

      3 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:05:52 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Forte Steve

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/4/25 4:15:09 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

      Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

      5/7/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare

      4/26/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2

      1/8/24 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Repare Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

      6/9/23 7:34:45 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

      2/3/23 7:35:18 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Repare Therapeutics with a new price target

      CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

      1/6/23 8:30:21 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Financials

    Live finance-specific insights

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

      Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

      12/12/24 4:20:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

      Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

      12/10/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RPTX
    SEC Filings

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

      Repare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. "We have taken careful steps to evaluate all aspects of our business to ensure continued value generation,

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Ap

      4/25/25 1:00:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      5/1/25 7:08:02 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Repare Therapeutics Inc.

      DEFA14A - Repare Therapeutics Inc. (0001808158) (Filer)

      4/29/25 4:10:31 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Repare Therapeutics Inc.

      DEF 14A - Repare Therapeutics Inc. (0001808158) (Filer)

      4/29/25 4:05:33 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:00:57 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 5:05:19 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:42:55 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care